Clinical trials: Asthma
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children
The purpose of this study is to demonstrate that CHF 1535 in pressurized metered dose inhaler (pMDI) is non-inferior to the corresponding dose of free combination of Beclomethasone (BDP) and Formoterol Fumarate (FF) and superior…
- Trial name
- PAED2/FRESH (NCT01475032)
- Testing
- CHF 1535, Beclomethasone (BDP), Beclomethasone (BDP) + Formoterol Fumarate (FF)
- Where
- 11 sites in Bulgaria, France and 9 more
- Volunteers
- 638 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
The primary objective is to compare the effects of Symbicort SiT and treatment according to NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by PD20 histamine, and to validate the Bronchial…
- Trial name
- NCT00235911
- Testing
- budesonide/formoterol Turbuhaler
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
House Dust Mite Allergy, House Dust Mite Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust…
- Trial name
- NCT06920771
- Testing
- PURETHAL Mites 50,000 AUeq/ml
- Where
- 68 sites in Bulgaria, Germany and 3 more
- Volunteers
- 691 people
- Sponsor
- HAL Allergy
Asthma
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)
The aim of this study is to evaluate the involvement of small airways in asthma, as determined by bronchial challenges, CT-scanning, and cellular markers of inflammation. Ciclesonide will be inhaled at one dose level once daily.
- Trial name
- NCT00163345
- Testing
- Ciclesonide
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Asthma
Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.
The Kata® App is a digital therapy assistant for patients with asthma who need to inhale their therapy. Kata features inhalation trainers that shows patients in a simple and understandable way how to improve their inhalation…
- Trial name
- NCT06178341
- Testing
- Kata Inhalations-App
- Where
- 13 sites in Germany
- Volunteers
- 146 people
- Sponsor
- VisionHealth GmbH
Asthma
Multiple Dose ASM8 in Mild Asthmatics
To determine the safety and efficacy of multiple doses of ASM8 antisense oligonucleotides in asthmatics.
- Trial name
- NCT00264966
- Testing
- ASM8
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Syntara
Asthma
GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects
GSK2190915 is currently in development for the treatment of asthma. This study aims to assess the safety and tolerability of single doses of GSK2190915 in healthy Japanese subjects.
- Trial name
- NCT00955383
- Testing
- GSK2190915
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three AMP provocation tests performed on one day
- Trial name
- NCT00272753
- Testing
- budesonide/formoterol Turbuhaler, formoterol Turbuhaler, salbutamol
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Asthma
A 12-Week Study in Adult Subjects With Asthma
This will be a multi-center, randomized, placebo controlled parallel-group study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma.
- Trial name
- NCT01516086
- Testing
- Fluticasone Propionate (FP)
- Where
- United States
- Volunteers
- 498 people
- Sponsor
- Dey
Asthma
Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
- Trial name
- SOURCE (NCT03406078)
- Testing
- Tezepelumab
- Where
- 60 sites in United States, Argentina and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Asthma
Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers
The objective of this study is to evaluate the pharmacokinetics (PK) and safety profiles of A006, an Albuterol dry powder inhaler (DPI), following a single dose of 110 mcg (T1) or 220 mcg (T2), in healthy male and female adult…
- Trial name
- A006-D (NCT02271334)
- Testing
- A006 DPI, Proventil® MDI
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®
The study is being conducted to compare the pharmacokinetic (PK) of BDP (and its main active metabolite B17MP), FF, and GB between CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI and CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI (pressurized…
- Trial name
- NCT05898984
- Testing
- Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI, Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI, Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)
- Where
- Belgium
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
The main objective of this study is to evaluate the efficacy and safety of the Armstrong's Epinephrine HFA-MDI (E004) formulation, in comparison to the Placebo (Placebo-HFA) and an Active Control (Epinephrine CFC-MDI), and to…
- Trial name
- NCT01025648
- Testing
- E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Exercise Induced Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
1. The primary objective of this study is: To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol on an as-needed basis compared to the use of terbutaline as-needed on exercise induced…
- Trial name
- MIA (NCT00989833)
- Testing
- budesonide, terbutaline, budesonide/formoterol
- Where
- 10 sites in Norway, Sweden
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Cat Allergy
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00867906
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Circassia Limited
Uncontrolled and Suspected Eosinophilic Asthma
A Phase IIa Study of KHK4563
This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma exacerbation rate in adult subjects with uncontrolled…
- Trial name
- 4563-003 (NCT01412736)
- Testing
- KHK4563
- Where
- 29 sites in Japan, South Korea
- Volunteers
- 106 people
- Sponsor
- Kyowa Kirin Co., Ltd.
COVID-19, Coronavirus Infections
Audio Data Collection for Identification and Classification of Coughing
An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.
- Conditions
- COVID-19, Coronavirus Infections, Hay Fever, Asthma
- Trial name
- NCT04326309
- Where
- United States
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- HealthMode Inc.
Asthma, Allergic
Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.
The main objective of this study is to evaluate, in real life, the efficacy of prolonged use (6 months) of Puressentiel Air Purifying Spray with 41 essential oils on the control of allergy-induced asthma in the homes of patients…
- Trial name
- PSIndAC (NCT05352126)
- Testing
- Biocide
- Volunteers
- 80 people
- Sponsor
- Puressentiel
Asthma
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo…
- Trial name
- NCT00393991
- Testing
- Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
- Where
- 57 sites in United States, Canada
- Volunteers
- 475 people
- Sponsor
- SkyePharma AG